New hope for transplant patients battling severe immune rejection

NCT ID NCT05531786

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

Summary

This study is testing an oral drug called pacritinib for adults with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after at least two prior treatments. cGVHD is a serious immune reaction that can occur after a stem cell transplant. The goal is to see if pacritinib is safe and can help control the disease in people who have run out of other options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-••••
University of Miami
RECRUITING

Miami, Florida, 33101, United States

Conditions

Explore the condition pages connected to this study.

GRAFT VS HOST DISEASE